atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit Post published:October 6, 2023 Post category:Press Release
Reunion Neuroscience Inc. to Participate in October Investor Conferences Post published:October 5, 2023 Post category:Press Release
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th Post published:October 5, 2023 Post category:Press Release
Sunstone Therapies Announces Expansion of Innovative Dyad Study Post published:October 3, 2023 Post category:Press Release
Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research Post published:October 3, 2023 Post category:Press Release
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants Post published:October 3, 2023 Post category:Press Release
Disposition of Common Shares of Small Pharma Inc. Post published:October 3, 2023 Post category:Press Release
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression Post published:September 29, 2023 Post category:Press Release
FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING LED BY NEGEV CAPITAL Post published:September 29, 2023 Post category:Press Release
Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program Post published:September 27, 2023 Post category:Press Release